Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering a self-organized enzyme cascade for enhanced cell-free biosynthesis of 3-hydroxypropionic acid.

Protein science : a publication of the Protein Society·2026
Same author

Focused Ultrasound-Triggered Burst Release and Enrichment of Engineered Bacteria for Tumor Therapy.

Biomaterials research·2026
Same author

Orthogonal Tri-Modular Coiled-Coil Assembly for Programmable Multi-Cargo Display on Escherichia coli Nissle 1917.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

A Self-Cross-Linked Dual-Enzyme Assembly for Safe and Efficient Hyperuricemia Therapy.

Biomacromolecules·2026
Same author

Engineered Vibrio natriegens as a living biocatalyst for in-situ biodegradation of microplastics in seawater.

Marine pollution bulletin·2026
Same author

Self-Decorating Albumin Nanoparticles as a Modular Drug Delivery Platform.

ACS biomaterials science & engineering·2025

Related Experiment Video

Updated: Dec 20, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.5K

Fine-tuning bispecific therapeutics.

Sung In Lim1

  • 1Department of Chemical Engineering, Pukyong National University, Yongso-ro 45, Nam-gu, Busan, South Korea.

Pharmacology & Therapeutics
|May 26, 2020
PubMed
Summary

Bispecific therapeutics offer unique advantages by targeting two antigens. Fine-tuning their design, including affinity, valency, and geometry, is crucial for optimal dual-target engagement and clinical success.

Keywords:
BiologicsBiotherapeuticsBispecific antibodyBispecific proteinBispecific therapyDrug delivery

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.0K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Related Experiment Videos

Last Updated: Dec 20, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.5K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.0K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K

Area of Science:

  • Biotechnology
  • Immunology
  • Drug Development

Background:

  • Bispecific therapeutics simultaneously engage two distinct antigens, offering functionalities beyond monospecific agents or combinations.
  • The field has seen significant growth in bispecific antibody formats, with over 100 developed in the last decade.
  • Despite progress in format diversity, optimizing dual-target engagement requires deeper understanding of target biology and format interplay.

Purpose of the Study:

  • To review the critical design parameters for bispecific therapeutics.
  • To guide the development of bispecific formats for enhanced dual-target engagement.
  • To facilitate the clinical translation of novel bispecific therapies.

Main Methods:

  • Review of current literature on bispecific antibody formats and design principles.
  • Analysis of factors influencing dual-target engagement, including affinity, valency, and geometry.
  • Discussion of the spatiotemporal interdependence of binding specificities and target biology.

Main Results:

  • Identification of key design parameters: affinity, valency, and geometry.
  • Emphasis on the need for qualitative fine-tuning of bispecific formats.
  • Highlighting the importance of understanding complex target biology for bispecific approaches.

Conclusions:

  • Early-stage consideration of design parameters is essential for maximizing the potential of bispecific therapeutics.
  • Optimized bispecific formats require a nuanced understanding of molecular interactions and biological context.
  • Further refinement of bispecific design will accelerate clinical translation and therapeutic efficacy.